These authors contributed equally to this work.
Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold
Version of Record online: 1 JAN 2009
Copyright © 2004 The Protein Society
Volume 13, Issue 7, pages 1882–1891, July 2004
How to Cite
Nicaise, M., Valerio-Lepiniec, M., Minard, P. and Desmadril, M. (2004), Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold. Protein Science, 13: 1882–1891. doi: 10.1110/ps.03540504
- Issue online: 1 JAN 2009
- Version of Record online: 1 JAN 2009
- Manuscript Revised: 8 APR 2004
- Manuscript Accepted: 8 APR 2004
- Manuscript Received: 2 DEC 2003
- 1992a. The seven-stranded β-barrel structure of aponeocarzinostatin as compared to the immunoglobulin domain. Biochimie 74: 853–858. , , , , and
- 1992b. Three-dimensional solution structure of apo-neocarzinostatin from Streptomyces carzinostaticus determined by NMR spectroscopy. Eur. J. Biochem. 203: 505–511. , , , , and
- 1988. Single-chain antigen-binding proteins. Science 242: 423–426. , , , , , , , , , and
- 2003. Humanization of the anti-CD18 antibody 6.7: An unexpected effect of a framework residue in binding to antigen. Mol. Immunol. 39: 941–952. , , , , , and
- 1994. Sequential 1H, 13C, and 15N NMR assignments and solution conformation of apokedarcidin. Biochemistry 38: 11438–11452. , , , , , , , , , and
- 1996. Single antibody domains as small recognition units: Design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng. 9: 531–537. and
- 1996. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3: 803–811. , , , , , , , and
- 1991. Neocarzinostatin: Selective tryptophan oxidation and neocarzinostatin-chromophore binding to apo-neocarzinostatin. Chem. Pharm. Bull. (Tokyo) 39: 170–176. , , , , , , and
- 1996. Interactions of CD80 and CD86 with CD28 and CTLA4. J. Immunol. 158: 2700–2709. , , , , and
- 1994. The de novo design of an antibody combining site. Crystallographic analysis of the VL domain confirms the structural model. J. Mol. Biol. 238: 226–244. and
- 2002. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach. Biochemistry 42: 1517–1528. , , and
- 2003. Biophysical properties of human antibody variable domains. J. Mol. Biol. 325: 531–553. , , , and
- Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182: 319–326. and
- 1993. Naturally occurring antibodies devoid of light chains. Nature 363: 446–448. , , , , , , , and
- 1999. Exploiting antibody-based technologies to manage environmental pollution. Trends Biotechnol. 17: 290–296.
- 2000. Reinvestigation of the proteolytic activity of neocarzinostatin. J. Bacteriol. 182: 1812–1818. , , , , and
- 2003. In vitro evolution of the binding specificity of neocarzinostatin, an enediyne-binding chromoprotein. Biochemistry 42: 5674–5683. , , , , , and
- 1993. Phage display of peptides and protein domains. Curr. Opin. Struct. Biol. 3: 572–579.
- 1997. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol. 15: 62–70.
- 1999. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11: 548–557.
- 1965. Neocarzinostatin, an antitumor antibiotic of high molecular weight. J. Antibiot. (Tokyo) 18: 68–76. , , , and
- 1980. Roles of chromophore and apo-protein in neocarzinostatin action. Proc. Natl. Acad. Sci. 77: 1970–1974. , , and
- 2002. Antibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells. Int. J. Cancer 99: 138–148. , , and
- 2001. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46: 169–185.
- 1994. Sequential 1H NMR assignment of the complex of aponeocarzinostatin with ethidium bromide and investigation of protein–drug interactions in the chromophore binding site. Biochemistry 33: 10579–10590. , , and
- 1994. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 7: 1129–1135. , , , , and
- 1972. The preparation of guanidine hydrochloride. Methods Enzymol. 26: 43–50.
- 1997. Scaffolds for engineering novel binding sites in proteins. Curr. Opin. Struct. Biol. 7: 463–469. and
- 1986. Determination and analysis of urea and guanidine hydrochloride denaturation curves. Methods Enzymol. 131: 266–280.
- 1995. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4: 2411–2423. , , , , and
- 1982. Actinoxanthin structure at the atomic level. Bioorganicheskaya Khimiya 8: 1637–1643. and
- 1988. Reshaping human antibodies for therapy. Nature 332: 323–327. , , , and
- 1993. The amino acid sequence of actinoxanthin apoprotein deduced from the base sequence of the gene. J. Antibiot. (Tokyo) 46: 1475–1477. , , , , and
- 2001. Gene transcription analysis of Saccharomyces cerevisiae exposed to neocarzinostatin protein–chromophore complex reveals evidence of DNA damage, a potential mechanism of resistance, and consequences of prolonged exposure. Proc. Natl. Acad. Sci. 98: 11075–11080. , , and
- 1995. Fermenter production of an artificial fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling. Proteins 23: 561–565. and
- 2000. Engineered protein scaffolds for molecular recognition. J. Mol. Recognit. 13: 167–187.
- 1991. Surface presentation of protein epitopes using bacteriophage expression systems. Curr. Opin. Biotechnol. 2: 668–673.
- 1996. The crystal structure of a llama heavy chain variable domain. Nat. Struct. Biol. 3: 752–757. , , , , , , , , and
- 2000. Release of the neocarzinostatin chromophore from the holoprotein does not require major conformational change of the tertiary and secondary structures induced by trifluoroethanol. J. Biol. Chem. 275: 39900–39906. , , and
- 1998. Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. Proteins 32: 515–522. , , , , and
- 2002. Solution structure of a novel chromoprotein derived from apo-neocarzinostatin and a synthetic chromophore. Biochemistry 41: 11731–11739. , , , , and
- 2002. Key interactions in neocarzinostatin, a protein of the immunoglobulin fold family. Protein Eng. 15: 861–869. , , , , and
- 2001. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J. Mol. Biol. 310: 591–601. , , , , , , and
- 1989. Crystal structure analysis of auromomycin apoprotein (macromomycin) shows importance of protein side chains to chromophore binding selectivity. Proc. Natl. Acad. Sci. 86: 6587–6591. and
- 1992. Rapid evolution of peptide and protein binding properties in vitro. Curr. Opin. Biotechnol. 3: 355–362. and
- 1994. C1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequence-specific double-strand DNA cleavage. Biochemistry 33: 5947–5954. , , , and